JP2009505640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009505640A5 JP2009505640A5 JP2008525635A JP2008525635A JP2009505640A5 JP 2009505640 A5 JP2009505640 A5 JP 2009505640A5 JP 2008525635 A JP2008525635 A JP 2008525635A JP 2008525635 A JP2008525635 A JP 2008525635A JP 2009505640 A5 JP2009505640 A5 JP 2009505640A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- antibody
- disease
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 14
- 239000003446 ligand Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108020004414 DNA Proteins 0.000 claims 4
- 102000053602 DNA Human genes 0.000 claims 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 230000009257 reactivity Effects 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001982 diacylglycerols Chemical class 0.000 claims 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 2
- 201000008980 hyperinsulinism Diseases 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000014311 Cushing syndrome Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010051161 Hyperglucagonaemia Diseases 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 206010043706 Thyroid cyst Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000001943 adrenal medulla Anatomy 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000035880 hyperglucagonemia Effects 0.000 claims 1
- 230000003832 immune regulation Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 210000002161 motor neuron Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000002571 pancreatic alpha cell Anatomy 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- -1 phospholipid glycan Chemical class 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000003699 striated muscle Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0516527A GB0516527D0 (en) | 2005-08-11 | 2005-08-11 | Peptides |
| GB0609921A GB0609921D0 (en) | 2006-05-18 | 2006-05-18 | Peptides |
| GB0609920A GB0609920D0 (en) | 2006-05-18 | 2006-05-18 | Peptides |
| PCT/GB2006/002977 WO2007017686A2 (en) | 2005-08-11 | 2006-08-09 | Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013024857A Division JP5738333B2 (ja) | 2005-08-11 | 2013-02-12 | 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009505640A JP2009505640A (ja) | 2009-02-12 |
| JP2009505640A5 true JP2009505640A5 (https=) | 2009-09-24 |
Family
ID=37056087
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525635A Pending JP2009505640A (ja) | 2005-08-11 | 2006-08-09 | 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド |
| JP2013024857A Expired - Fee Related JP5738333B2 (ja) | 2005-08-11 | 2013-02-12 | 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013024857A Expired - Fee Related JP5738333B2 (ja) | 2005-08-11 | 2013-02-12 | 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9243062B2 (https=) |
| EP (3) | EP2594591B1 (https=) |
| JP (2) | JP2009505640A (https=) |
| KR (2) | KR20080039978A (https=) |
| CN (1) | CN105017423B (https=) |
| AU (1) | AU2006277785B2 (https=) |
| BR (1) | BRPI0614366A2 (https=) |
| CA (1) | CA2618796C (https=) |
| CU (1) | CU23793B7 (https=) |
| CY (1) | CY1120640T1 (https=) |
| DK (1) | DK2594591T3 (https=) |
| EA (1) | EA015629B1 (https=) |
| ES (1) | ES2679994T3 (https=) |
| GB (1) | GB2429013C (https=) |
| IL (3) | IL189407A (https=) |
| NZ (3) | NZ595387A (https=) |
| WO (1) | WO2007017686A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
| PL2289909T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| EP2154969B1 (en) | 2007-05-16 | 2015-11-18 | The Brigham and Women's Hospital, Inc. | Treatment of synucleinopathies |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| EP2527366B1 (en) * | 2007-06-12 | 2017-08-16 | AC Immune S.A. | Monoclonal anti beta amyloid antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| RS53174B (sr) | 2007-10-05 | 2014-06-30 | Genentech Inc. | Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka |
| US20110256577A1 (en) * | 2008-11-05 | 2011-10-20 | Fujirebio Inc. | Method for sensing a biochemical and/or biomechanical process of a biological material and method for analyzing biological materials |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| RU2607368C2 (ru) | 2010-07-30 | 2017-01-10 | Ац Иммуне С.А. | Безопасные и функциональные гуманизированные антитела |
| CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| WO2012047732A2 (en) * | 2010-09-29 | 2012-04-12 | Genentech, Inc. | Antibody compositions and methods of use |
| JP5937106B2 (ja) * | 2011-01-20 | 2016-06-22 | サイレックス ラボラトリーズ，エルエルシー | グルテン感受性の検出およびグルテン感受性とセリアック病を鑑別するための方法ならびに装置 |
| KR102437522B1 (ko) * | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| JP6153019B2 (ja) | 2013-01-31 | 2017-06-28 | 国立大学法人 東京大学 | リゾホスファチジルセリン受容体機能調節活性を有する化合物 |
| ES2729797T3 (es) * | 2013-12-20 | 2019-11-06 | Dev Ct Biotechnology | Anticuerpos específicos de la alfa-enolasa y métodos de uso en terapias contra el cáncer |
| WO2015114576A1 (en) * | 2014-01-31 | 2015-08-06 | Universität Zürich | Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease |
| JP6369721B2 (ja) | 2014-07-04 | 2018-08-08 | 国立大学法人 東京大学 | リゾホスファチジルセリン誘導体 |
| GB2532426B (en) * | 2014-11-18 | 2016-11-02 | Rogers Arpi | Therapeutic homodimer and uses thereof |
| WO2016108894A1 (en) * | 2014-12-31 | 2016-07-07 | Develpment Center For Biotechnology | Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy |
| US9527922B2 (en) | 2014-12-31 | 2016-12-27 | Development Center For Biotechnology | Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy |
| JP6404950B2 (ja) * | 2015-01-21 | 2018-10-17 | ギル メディカル センターＧｉｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | ホスファチジルイノシトールリン酸結合物質の細胞死滅検出用途 |
| JP6544669B1 (ja) | 2018-03-16 | 2019-07-17 | ディヴェロップメント センター フォー バイオテクノロジー | アルファエノラーゼに特異的な抗体及びその使用 |
| WO2019197610A1 (en) | 2018-04-13 | 2019-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New vaccinal strategy |
| CN110885778A (zh) * | 2018-09-07 | 2020-03-17 | 上海益诺思生物技术股份有限公司 | 从体外培养的细胞中分离Pig-a基因突变细胞的方法 |
| JP7796008B2 (ja) * | 2019-09-13 | 2026-01-08 | メモリアル スローン ケタリング キャンサー センター | 抗ｃｄ３７１抗体およびその使用 |
| GB202015755D0 (en) * | 2020-10-05 | 2020-11-18 | Rogers Arpi | Coronavirus therapy |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| EP0463056A1 (en) | 1989-03-17 | 1992-01-02 | E.I. Du Pont De Nemours And Company | External regulation of gene expression |
| EP0628639B1 (en) | 1991-04-25 | 1999-06-23 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| SE9102074D0 (sv) * | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| US5891623A (en) | 1992-11-09 | 1999-04-06 | Consorzio Per Le Biotecnologie | Diagnosis and treatment of AIDS onset |
| GB9317423D0 (en) | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
| US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
| US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| US6001809A (en) | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
| USRE39048E1 (en) * | 1995-06-07 | 2006-03-28 | Pepscan Systems B.V. | Peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine |
| US5861260A (en) * | 1996-11-05 | 1999-01-19 | University Of Massachusetts | Diagnostic methods for screening patients for scleroderma |
| IL121041A0 (en) * | 1997-06-09 | 1997-11-20 | Yeda Res & Dev | Immunogenic compositions for induction of anti-tumor immunity |
| NZ501424A (en) * | 1997-07-21 | 2005-08-26 | Arpi Matossian Rogers | Ligands, including antibodies, showing reactivity against anti-TCR V-beta antibody |
| DE19739685A1 (de) | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
| US7083950B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| US6703491B1 (en) * | 1999-03-17 | 2004-03-09 | Exelixis, Inc. | Drosophila sequences |
| IL148079A0 (en) * | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| PT1232392E (pt) | 1999-10-12 | 2003-08-29 | Connex Ges Optimierung Von For | Processo melhorado para deteccao nas fezes de bacterias do genero helicobacter resistentes ao acido |
| EP1130032A1 (en) | 2000-02-28 | 2001-09-05 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR) |
| GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| JP2001299349A (ja) * | 2000-04-19 | 2001-10-30 | Suntory Ltd | 新規組換え型抗体とそのｃｄｒのアミノ酸配列およびそれをコードする遺伝子 |
| CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| US20040115196A1 (en) * | 2001-04-18 | 2004-06-17 | Yoshiaki Fukuda | Novel recombinant antibodies, amino acid sequences of cdrs thereof and genes encoding the same |
| EP2277542B1 (en) * | 2001-06-01 | 2014-04-16 | Cornell Research Foundation Inc. | Modified antibodies to prostrate-specific membrane antigen and uses thereof |
| IL159422A0 (en) | 2001-09-20 | 2004-06-01 | Cornell Res Foundation Inc | Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen |
| WO2003074566A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Rs7 antibodies |
| BR0312985A (pt) * | 2002-07-26 | 2005-06-21 | Inst Medical W & E Hall | Métodos para extrair ou induzir, em um mamìfero, uma resposta imune dirigida a um parasita, para tratar de modo terapêutico ou profilático um mamìfero para infecção por parasitas, para o tratamento e/ou a profilaxia de uma condição doentia de mamìfero, uso de uma composição,composição, composição de vacina, composição farmacêutica, anticorpo para inibir, parar ou retardar o inìcio ou progressão de uma condição doentia de mamìfero, uso de um anticorpo, métodos para detectar, em uma amostra bológica, uma molécula imunointerativa dirigida a um microorganismo e para detectar, monitorar ou de outra forma avaliar uma resposta imune dirigida a um microorganismo em um indivìduo, kit modular, método para analisar, projetar e/ou modificar um agente capaz de interagir com um sìtio de ligação de molécula imunointerativa anti-gpi glicano, e, uso do agente |
| US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| US20040136998A1 (en) | 2002-10-30 | 2004-07-15 | Bander Neil H. | Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen |
| WO2005035732A2 (en) * | 2003-02-19 | 2005-04-21 | Dyax Corporation | Papp-a ligands |
| KR100500283B1 (ko) | 2003-03-25 | 2005-07-11 | 이뮤노믹스 주식회사 | 인간 4-1비비 분자에 대한 인간화 모노클로날 폴리펩티드 및 이를 포함하는 약학 조성물 |
| KR100872210B1 (ko) | 2003-04-23 | 2008-12-05 | 메다렉스, 인코포레이티드 | 인터페론 알파 수용체-1 (ｉｆｎａｒ-1)에 대한 인체화항체 |
| CA2528182A1 (en) | 2003-06-06 | 2005-06-16 | Oncomax Acquisition Corp. | Antibodies specific for cancer associated antigen sm5-1 and uses thereof |
| AU2004261229A1 (en) * | 2003-07-29 | 2005-02-10 | Eisai, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| US9403908B2 (en) | 2003-09-29 | 2016-08-02 | The Regents Of The University Of California | Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration |
| KR101413844B1 (ko) * | 2008-12-09 | 2014-06-30 | 화이자 백신스 엘엘씨 | ＩｇＥ ＣＨ３ 펩티드 백신 |
-
2006
- 2006-08-09 CA CA2618796A patent/CA2618796C/en not_active Expired - Fee Related
- 2006-08-09 US US11/990,281 patent/US9243062B2/en not_active Expired - Fee Related
- 2006-08-09 EA EA200800556A patent/EA015629B1/ru not_active IP Right Cessation
- 2006-08-09 EP EP12198289.6A patent/EP2594591B1/en active Active
- 2006-08-09 KR KR1020087005824A patent/KR20080039978A/ko not_active Ceased
- 2006-08-09 GB GB0615831A patent/GB2429013C/en not_active Expired - Fee Related
- 2006-08-09 WO PCT/GB2006/002977 patent/WO2007017686A2/en not_active Ceased
- 2006-08-09 NZ NZ595387A patent/NZ595387A/xx not_active IP Right Cessation
- 2006-08-09 ES ES12198289.6T patent/ES2679994T3/es active Active
- 2006-08-09 BR BRPI0614366-0A patent/BRPI0614366A2/pt not_active Application Discontinuation
- 2006-08-09 JP JP2008525635A patent/JP2009505640A/ja active Pending
- 2006-08-09 KR KR1020147008188A patent/KR101527334B1/ko not_active Expired - Fee Related
- 2006-08-09 AU AU2006277785A patent/AU2006277785B2/en not_active Ceased
- 2006-08-09 EP EP12198288.8A patent/EP2578602B1/en active Active
- 2006-08-09 CN CN201510292155.1A patent/CN105017423B/zh not_active Expired - Fee Related
- 2006-08-09 NZ NZ566245A patent/NZ566245A/en not_active IP Right Cessation
- 2006-08-09 NZ NZ595386A patent/NZ595386A/xx not_active IP Right Cessation
- 2006-08-09 EP EP06779101.2A patent/EP1919952B1/en active Active
- 2006-08-09 DK DK12198289.6T patent/DK2594591T3/en active
-
2008
- 2008-02-10 IL IL189407A patent/IL189407A/en not_active IP Right Cessation
- 2008-02-11 CU CU20080021A patent/CU23793B7/es active IP Right Grant
-
2012
- 2012-11-05 IL IL222880A patent/IL222880A/en active IP Right Grant
- 2012-11-05 IL IL222879A patent/IL222879A/en not_active IP Right Cessation
-
2013
- 2013-02-12 JP JP2013024857A patent/JP5738333B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-16 CY CY181100863T patent/CY1120640T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009505640A5 (https=) | ||
| CN101048659B (zh) | 抗前胃泌素单克隆抗体 | |
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| US11046745B2 (en) | Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof | |
| US9221889B2 (en) | VEGF-specific capture agents, compositions, and methods of using and making | |
| CN102143978B (zh) | 抗p2x7肽和表位 | |
| JP2007536212A (ja) | レプチンアンタゴニストおよびレプチン定量測定方法 | |
| KR20160007579A (ko) | 면역요법의 임상 효과의 예측법 | |
| CN113227148A (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| JP4705694B2 (ja) | イミュノグロブリン結合能を有するペプチド | |
| Balhorn et al. | Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia | |
| CN117242092A (zh) | Vegfa结合分子 | |
| WO2021213245A1 (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
| JPH02479A (ja) | ｓｎＲＮＰ−Ａ抗原及びそのフラグメント | |
| CA2401580A1 (en) | Affinity matrix bearing tumor-associated antigens | |
| CN102014955A (zh) | 含醣基广谱癌症标志物 | |
| WO2016077720A1 (en) | Binding agents and uses thereof | |
| US10570185B2 (en) | Method to detect autoantibody reactivity for deamidated insulin autoantigen in diabetes | |
| WO2010069570A2 (en) | Peptides against autoantibodies associated with crps and use of these peptides | |
| CN119505001B (zh) | 靶向cd22的全人源抗体及其应用 | |
| Itoh et al. | Antibody epitope peptides as potential inducers of IgG antibodies against CD98 oncoprotein | |
| US10975122B2 (en) | Epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection | |
| WO2025081063A2 (en) | Antibody-drug conjugate metabolites | |
| WO2024153146A1 (zh) | 抗nmda受体自身免疫性脑炎新型抗体及其用途 | |
| WO2025069026A1 (en) | Lateral flow assay device and method for rapid detection of fentanyl and fentanyl analogs |